| Literature DB >> 28963313 |
Esther P W A Talboom-Kamp1,2, Noortje A Verdijk1,2, Marise J Kasteleyn1, Lara M Harmans2, Irvin J S H Talboom3, Mattijs E Numans1, Niels H Chavannes1.
Abstract
OBJECTIVES: To analyse the effect on therapeutic control and self-management skills of the implementation of self-management programmes, including eHealth by e-learning versus group training.Entities:
Keywords: zzm321990–oral anticoagulation; TTR; e-learning; eHealth; self-efficacy; self-management; self-monitoring.; thrombosis
Mesh:
Substances:
Year: 2017 PMID: 28963313 PMCID: PMC5623459 DOI: 10.1136/bmjopen-2017-017909
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Overview of the study design: details of groups 1, 2 and 3
| Saltro Thrombosis Service Centre | |||
| Self-management | Usual care | ||
| Patients | Group 1 | Group 2 | Group 3 |
| #72 | #72 | #72 | |
| Instruction | E-learning | Group course | Basic short training |
| Disease-specific knowledge | Disease-specific knowledge | ||
| Platform | Self-management | Self-management | |
Training methods in group 1, 2 and 3
| Group 1 | Group 2 | Group 3 |
| General education (e-learning) about anticoagulation+test | Group course with training self-testing+use of web portal | Basic training |
| Self-testing device | Self-testing device | Venipuncture at home or in facilities |
| Control and quality check by nurse | Control and quality check by nurse | Written instructions by thrombosis doctor |
Figure 1Flowchart of the PORTALS study.
Clinical characteristics of the population of the Saltro Thrombosis Service
| Total patients, N | 11 132 |
| Male, N (%) | 6009 (54.0) |
| Self-management, N (%) | 1986 (17.8) |
| Male self-management, N (%) | 1260 (63.4) |
| Medication, N (%) | |
| Acenocoumarol | 8360 (75.1) |
| Phenprocoumon | 2761 (24.8) |
| Warfarin | 11 (0.1) |
| Indications, N (%) | |
| Atrial fibrillation | 7430 (66.8) |
| Venous thromboembolism | 1673 (15.0) |
| Artificial valve | 720 (6.5) |
| Other | 1309 (11.8) |
| Severe complications, N (%) | |
| Major bleedings | 219 (2.0) |
| Thromboembolism | 85 (0.8) |
Baseline characteristics of patients with VKA therapy in the PORTALS study
| Group 1 | Group 2 | Group 3 | p Value | Total | |
| N | 63 | 74 | 110 | ||
| Age in years* (IQR) | 65.0a (56.2–67.7) | 65.8a (56.4–70.4) | 69.6b (64.0–74.9) | 0.00† | 66.9 (59.5–72.7) |
| Males, N (%) | 47 (74.6) | 52 (70.3) | 81 (73.6) | 0.826 | 180 (72.9) |
| TTR INR range 2-3 (%)* (IQR) | 50.2 (39.1–67.1) | 52.9 (39.0–68.6) | 57.4 (40.1–75.1) | 0.159 | 54.7 (39.8–70.7) |
| TTR INR range 2-3.5 (%)* (IQR) | 76.3 (67.0–86.0) | 77.1 (64.1–85.3) | 85.6 (72.0–93.5) | 0.159 | 79.1 (68.2–88.8) |
| GSES* (IQR) | 3.5a (3.1–3.8) | 3.3a,b (3.0–3.7) | 3.1b (2.9–3.5) | 0.001† | 3.3 (3.0–3.7) |
| EQ-5D* (IQR) | 1.0a (0.81–1.0) | 0.84a,b (0.78–1.0) | 0.84b (0.78–1.0) | 0.036† | 0.84 (0.81–1.0) |
| Indication, N (%) | |||||
| AF | 42 (66.7) | 44 (59.5) | 77 (70.0) | 0.215 | 163 (66) |
| Venous thromboembolism | 13 (20.6) | 18 (24.3) | 11 (10.0) | 42 (17) | |
| Artificial valve | 2 (3.2) | 3 (4.1) | 4 (3.6) | 9 (3.6) | |
| Other | 6 (9.5) | 9 (12.2) | 18 (16.4) | 33 (13.4) | |
| Medication, N (%) | |||||
| Acenocoumarol | 51 (81)a | 64 (86.5)a | 76 (69.1)b | 0.004† | 191 (77.3) |
| Phenprocoumon | 10 (15.9)a | 10 (13.5)a | 34 (30.9)b | 54 (21.9) | |
| Warfarin | 2 (3.2)a | 0 (0)a | 0 (0)a | 2 (0.8) | |
| Education level, N (%) | |||||
| Low | 7 (12.1)a | 13 (19.1)a | 33 (35.9)b | 0.00† | 53 (24.3) |
| Medium | 24 (41.4)a | 32 (47.1)a | 46 (50.0)a | 102 (46.8) | |
| High | 27 (46.6)a | 23 (33.8)b | 13 (14.1)c | 63 (28.9) | |
| Marital status, N (%) | |||||
| Married | 49 (84.5) | 50 (73.5) | 73 (79.3) | 0.280 | 172 (78.9) |
| Widow | 1 (1.7) | 6 (8.8) | 4 (4.3) | 11 (5.0) | |
| Divorced | 1 (1.7) | 6 (8.8) | 4 (4.3) | 11 (5.0) | |
| Single | 7 (12.1) | 6 (8.8) | 11 (12.0) | 24 (11.0) | |
| Labour, N (%) | |||||
| No paid work | 28 (48.3)a | 29 (42.6)a | 39 (42.4)a | 0.043† | 96 (44.0) |
| Paid work | 19 (32.8)a | 20 (29.4)a | 14 (15.2)b | 53 (24.3) | |
| Household | 8 (13.8)a | 11 (16.2)a | 23 (25.0)a | 42 (19.3) | |
| Incapacitated | 3 (5.2)a | 8 (11.8)a | 16 (17.4)a | 27 (12.4) |
Each superscript (a,b,c) letter denotes a subset of sample categories which do not differ significantly from each other at the 0.05 level.
N Missing questionnaires: GSES 29, EQ5D 32, indication 0, medication 0, education 29, marital status 29, labour 29.
*Values are medians and corresponding IQR.
†Between-group differences (p<0.05).
AF, atrial fibrillation; EQ-5D, EuroQol five dimensions questionnaire; INR, international normalised ratio; GSES, General Self-efficacy Scale; TTR, time in therapeutic range; VKA, vitamin K antagonist.
Figure 2A Health status based on TTR (for INR range 2–3) for the three groups. INR, international normalised ratio; TTR, time in therapeutic.
Figure 3Usage of the platform in group 1 and group 2 after start of the intervention.